SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-24-025675
Filing Date
2024-02-20
Accepted
2024-02-20 19:11:01
Documents
1
Group Members
DR. JAMES I. HEALYDR. MAHA KATABISOFINNOVA MANAGEMENT X, L.P.SOFINNOVA MANAGEMENT X-A, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm246499d4_sc13da.htm SC 13D/A 133658
  Complete submission text file 0001104659-24-025675.txt   135487
Mailing Address 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025
Business Address 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 650-681-8420
Sofinnova Venture Partners X, L.P. (Filed by) CIK: 0001680200 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91586 | Film No.: 24655772
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)